Humacyte, INC 8-K filings

Humacyte announced positive Q2 2026 results, highlighting breakthrough Phase 3 data for its dialysis access product and progress in its coronary artery bypass graft program.

Humacyte, Inc. received a notification from Nasdaq regarding its common stock bid price falling below the $1.00 minimum requirement, triggering a 180-day compliance period.

Humacyte, Inc. has priced an underwritten public offering of 47,619,048 shares of its common stock at $1.05 per share to raise approximately $50 million in gross proceeds.

Humacyte's Phase 3 V012 study of its acellular tissue engineered vessel (ATEV) for dialysis access in female patients met its primary endpoint, showing superior catheter-free days compared to standard AV fistula.

Humacyte, Inc. announced the approval of an amendment to increase its authorized common stock shares from 350 million to 550 million, effective June 9, 2026.

Humacyte, Inc. has officially regained compliance with Nasdaq's minimum bid price requirement for continued listing.

Humacyte, Inc. has been notified by Nasdaq that its common stock has fallen below the minimum $1.00 bid price requirement for continued listing.

Humacyte, Inc. has amended its distribution agreement with Fresenius Medical Care, regaining exclusive worldwide rights to its Symvess acellular tissue engineered vessel, while agreeing to pay low-single-digit royalties on ex-U.S. sales.

Humacyte, Inc. announced a registered direct offering of 25 million common shares at $0.80 each, raising approximately $18.4 million net to fund commercialization and pipeline development.

Humacyte, Inc. announced the suspension of its $60 million ATM offering, provided preliminary 2025 financial estimates, and detailed international commercial and regulatory advancements for Symvess.

Humacyte, Inc. has entered into a sales agreement with TD Securities (USA) LLC to offer and sell up to $60 million of its common stock through an at-the-market offering.

Humacyte, Inc. has entered into a new senior secured term loan facility of up to $77.5 million and issued warrants to Avenue Venture Opportunities Fund II, L.P. to bolster its financial position and fund operations.

Humacyte, Inc. has terminated its Revenue Interest Purchase Agreement and Option Agreement, agreeing to pay $38 million in cash and issue 5,725,190 shares of common stock.

Humacyte, Inc. has terminated its Open Market Sale Agreement with Jefferies LLC, ending its ability to sell up to $80 million in common stock.

Humacyte reports substantial Q3 2025 revenue growth driven by Symvess sales, positive clinical data for ATEV in dialysis, and pipeline progress for CTEV.

Humacyte, Inc. announced the pricing of an oversubscribed registered direct offering, raising approximately $60.0 million through the sale of common stock and warrants.

Humacyte, Inc. amended its Revenue Interest Purchase Agreement, making a $50 million debt repayment and securing a discounted $95.5 million call option for early debt repurchase.

Humacyte reported significant commercial progress for Symvess in Q2 2025, including expanded hospital access and strong July sales, alongside strategic cost reductions and positive clinical trial data for its dialysis application.

Humacyte, Inc. announced that its stockholders approved an amendment to increase the authorized common stock from 250 million to 350 million shares and re-elected four Class I directors at its 2025 Annual Meeting.

Humacyte reports first quarter 2025 financial results, highlighted by the commercial launch of Symvess and total revenues of $517,000.

Humacyte defends its life-saving work against a citizen petition, alleging conflicts of interest among the signatories.

Humacyte announces FDA approval and commercial launch of Symvess for extremity vascular trauma, along with financial results for Q4 and full year 2024.

Humacyte's CEO addresses concerns raised in a New York Times article regarding the FDA approval of Symvess, emphasizing the rigorous review process and the product's safety and effectiveness.

Humacyte, a commercial-stage biotechnology company, has announced the pricing of a $50 million underwritten public offering of its common stock.

Humacyte's investor presentation highlights the U.S. market launch of Symvess for vascular trauma and progress in its pipeline of regenerative medicine products.

Humacyte has secured FDA approval for SYMVESS, a bioengineered tissue vessel, for use in adults with extremity arterial injuries requiring urgent revascularization when a vein graft is not feasible.

Humacyte, a clinical-stage biotechnology company, has announced a $15 million registered direct offering of common stock and warrants to fund its bioengineered tissue development.

Humacyte reported its third quarter 2024 financial results, highlighted progress on its ATEV product, and provided an update on the FDA review process.

Humacyte's acellular tissue engineered vessel (ATEV) demonstrated superior function and patency compared to autogenous fistula in a Phase 3 clinical trial for hemodialysis access, particularly in female, obese, and diabetic patients.

Humacyte, a clinical-stage biotech company, has announced a $30 million registered direct offering of common stock and warrants to fund its bioengineered tissue development.